PMID- 21376661
OWN - NLM
STAT- MEDLINE
DCOM- 20120815
LR  - 20151119
IS  - 1873-5967 (Electronic)
IS  - 1386-6532 (Linking)
VI  - 51
IP  - 1
DP  - 2011 May
TI  - Different characteristics of human herpesvirus 6 encephalitis between primary 
      infection and viral reactivation.
PG  - 12-9
LID - 10.1016/j.jcv.2011.02.002 [doi]
AB  - BACKGROUND: Pathogenesis of human herpesvirus 6 (HHV-6) encephalitis, in 
      particular difference between HHV-6 encephalitis at the time of primary infection 
      and reactivation remains unclear. OBJECTIVES: To elucidate the mechanism of HHV-6 
      encephalitis at the time of primary infection and reactivation. STUDY DESIGN: 
      Twenty-two HHV-6 encephalitis patients at the time of primary infection, 6 
      febrile convulsion (FC) patients caused by HHV-6 infection, and 14 FC patients 
      without HHV-6 infection (non HHV-6 FC) were enrolled. Additionally, 7 stem cell 
      transplant recipients with HHV-6 encephalitis and eight adult controls were also 
      enrolled in this study. Cerebrospinal fluid (CSF) HHV-6 DNA copy numbers and 
      biomarkers levels were compared. RESULTS: Low copy number of CSF HHV-6 DNA was 
      detected in 7 of the 22 patients with HHV-6 encephalitis in primary infection, 
      whereas all seven CSF samples collected from post-transplant HHV-6 encephalitis 
      patients contained high viral DNA copy numbers (P<0.001). CSF concentrations of 
      IL-6 (P=0.032), IL-8 (P=0.014), MMP-9 (P=0.004), and TIMP-1 (P=0.002) were 
      significantly higher in patients with HHV-6 encephalitis in primary infection 
      than non-HHV-6 FC. CSF IL-6 (P=0.008), IL-8 (P=0.015), and IL-10 (P=0.019) 
      concentrations were significantly higher in patients with post-transplant HHV-6 
      encephalitis than adult controls. CONCLUSION: The present study suggests that the 
      characteristics of HHV-6 encephalitis are different between HHV-6 encephalitis at 
      the time of primary infection and reactivation in transplant recipients.
CI  - Copyright (c) 2011 Elsevier B.V. All rights reserved.
FAU - Kawamura, Yoshiki
AU  - Kawamura Y
AD  - Department of Pediatrics, Fujita Health University School of Medicine, 1-98 
      Dengakugakubo, Kutsukake-cho, Toyoake, Aichi 4701192, Japan.
FAU - Sugata, Ken
AU  - Sugata K
FAU - Ihira, Masaru
AU  - Ihira M
FAU - Mihara, Takateru
AU  - Mihara T
FAU - Mutoh, Tatsuro
AU  - Mutoh T
FAU - Asano, Yoshizo
AU  - Asano Y
FAU - Yoshikawa, Tetsushi
AU  - Yoshikawa T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110303
PL  - Netherlands
TA  - J Clin Virol
JT  - Journal of clinical virology : the official publication of the Pan American 
      Society for Clinical Virology
JID - 9815671
RN  - 0 (Biomarkers)
RN  - 0 (DNA, Viral)
RN  - 0 (Interleukins)
RN  - 0 (Tissue Inhibitor of Metalloproteinase-1)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers/cerebrospinal fluid
MH  - Case-Control Studies
MH  - Child, Preschool
MH  - DNA, Viral/cerebrospinal fluid
MH  - Encephalitis, Viral/cerebrospinal fluid/*virology
MH  - Female
MH  - Herpesvirus 6, Human/genetics/pathogenicity/*physiology
MH  - Humans
MH  - Infant
MH  - Interleukins/cerebrospinal fluid
MH  - Male
MH  - Matrix Metalloproteinase 9/cerebrospinal fluid
MH  - Middle Aged
MH  - Polymerase Chain Reaction
MH  - Recurrence
MH  - Roseolovirus Infections/cerebrospinal fluid/*virology
MH  - Seizures, Febrile/virology
MH  - Tissue Inhibitor of Metalloproteinase-1/cerebrospinal fluid
MH  - Transplantation/statistics & numerical data
MH  - *Virus Activation
EDAT- 2011/03/08 06:00
MHDA- 2012/08/16 06:00
CRDT- 2011/03/08 06:00
PHST- 2010/07/03 00:00 [received]
PHST- 2010/12/28 00:00 [revised]
PHST- 2011/02/07 00:00 [accepted]
PHST- 2011/03/08 06:00 [entrez]
PHST- 2011/03/08 06:00 [pubmed]
PHST- 2012/08/16 06:00 [medline]
AID - S1386-6532(11)00070-9 [pii]
AID - 10.1016/j.jcv.2011.02.002 [doi]
PST - ppublish
SO  - J Clin Virol. 2011 May;51(1):12-9. doi: 10.1016/j.jcv.2011.02.002. Epub 2011 Mar 
      3.